SCHEMBL2768565

SCHEMBL2768565

CCOc1ccc(NC(=O)N(S)c2noc3cccc(N(C)C)c23)cc1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 7/20 0.43
RAB9A P51151 5/20 0.43
SMN1; SMN2 Q16637 5/20 0.43
NPC1 O15118 4/20 0.43
HSD17B10 Q99714 1/20 0.43
ALDH1A1 P00352 2/20 0.42
KDM4E B2RXH2 1/20 0.42
MITF O75030 1/20 0.42
PKM P14618 1/20 0.42
S1PR1 P21453 1/20 0.41
OPRM1 P35372 1/20 0.41
OPRD1 P41143 1/20 0.41
POLB P06746 2/20 0.40
LMNA P02545 2/20 0.40
MEN1 O00255 1/20 0.40
CYP1A2 P05177 1/20 0.40
KMT2A Q03164 1/20 0.40
TDP1 Q9NUW8 1/20 0.40
TP53 P04637 3/20 0.39
GBA1 P04062 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2768720 0.89 KIT (0.48) MAPTRAB9ASMN1; SMN2NPC1HSD17B10
SCHEMBL2768573 0.83 NOX1 (0.40) MAPTRAB9ANPC1ALDH1A1KDM4E
SCHEMBL2768628 0.83 HIF1A (0.47) MAPTRAB9ASMN1; SMN2NPC1HSD17B10
SCHEMBL2769970 0.81 HIF1A (0.49) MAPTRAB9ASMN1; SMN2NPC1ALDH1A1
SCHEMBL2768388 0.81 KIT (0.44) MAPTRAB9ASMN1; SMN2NPC1ALDH1A1
SCHEMBL2770452 0.77 SMN1; SMN2 (0.42) MAPTRAB9ASMN1; SMN2NPC1HSD17B10
SCHEMBL2768563 0.77 MAPT (0.52) MAPTRAB9ASMN1; SMN2NPC1ALDH1A1
SCHEMBL2769354 0.76 MAPT (0.48) MAPTRAB9ASMN1; SMN2NPC1ALDH1A1
SCHEMBL2769331 0.75 RAB9A (0.36) MAPTRAB9ASMN1; SMN2NPC1HSD17B10
SCHEMBL2770801 0.75 ALDH1A1 (0.42) MAPTRAB9ASMN1; SMN2NPC1HSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1881967-B1 SUBSTITUTED BENZO(D)ISOXAZOL-3-YL AMINE COMPOUNDS AS ANALGESICS GRUENENTHAL GMBH (DE) 2010-04-28 EP claimed
US-20080176915-A1 Substituted Benzo[d]isoxazol-3-yl Amine Compounds as Analgesics GRUENENTHAL GMBH (DE) 2008-07-24 US claimed
US-7696238-B2 Substituted benzo[d]isoxazol-3-yl amine compounds as analgesics GRUENENTHAL GMBH (DE) 2010-04-13 US disclosed
US-20080176915-A1 Substituted Benzo[d]isoxazol-3-yl Amine Compounds as Analgesics GRUENENTHAL GMBH (DE) 2008-07-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080176915-A1 Substituted Benzo[d]isoxazol-3-yl Amine Compounds as Analgesics KCNQ1, KCNQ2, KCNQ3 MAPT 2492/4885RAB9A 3127/4885SMN1; SMN2 1349/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.